Jefferies cuts Clorox stock price target on cost pressures

Jefferies cut its Clorox price target to $139 from $151 while keeping a Buy rating, citing ongoing cost pressures, market share losses, and third-quarter organic sales growth expected to miss by 50 bps. The firm also lowered fiscal 2026 and 2027 EPS estimates by 2% and 8%, and expects Clorox to reduce fiscal 2026 EPS guidance due to higher costs. Clorox has completed its GOJO Industries acquisition, while the article also notes mixed analyst actions and upcoming earnings on April 30.

Analysis

CLX is signaling a classic late-cycle margin reset: the market is still pricing in “temporary” inflation, but management commentary is increasingly about duration, which matters more than the next quarter’s EPS miss. The real second-order issue is that input-cost relief, if it comes, likely helps gross margin before it helps volume, because share losses in defended categories usually take multiple quarters to repair. That creates a window where sell-side downgrades can overshoot fundamentals on the downside, but only if the company proves it can stabilize share without another round of price-pack architecture mistakes.

The more important competitive dynamic is that CLX’s pain can become a relative winner for adjacent staples with cleaner brand momentum and less exposure to commodity pass-through risk. If shelf space is being reallocated, the near-term beneficiary is not necessarily the largest peer but the one with the least promotional intensity and best retailer negotiation leverage. In other words, this is less about a sector-wide demand problem and more about a company-specific execution tax that could persist through the next two reporting cycles.

The GOJO deal adds a subtle offset: it may improve the mix over time, but near-term integration usually delays any valuation rerating because investors focus on whether the acquired growth is additive or just diversifying away from core weakness. The market will likely demand evidence on fiscal 2027, not just guidance language, meaning the stock can stay range-bound until there is proof of share stabilization and cost normalization. A clean beat may not be enough; the catalyst has to be a reversal in estimate cuts, not just a smaller miss.

Key Decisions for Investors

• Short-dated downside protection on CLX into the April 30 earnings event: buy 1-2 month puts or put spreads to express the risk that guidance is revised again and shares re-test the low-$90s; best risk/reward if implied vol is not already pricing a full reset.
• Pair trade: long a higher-quality staples peer versus short CLX for 2-3 months, targeting relative outperformance if category share continues to leak away from CLX while broader staples remain defensive.
• If CLX sells off 5-8% on earnings without a further cut to long-term outlook, consider a tactical long for a 4-8 week mean reversion trade; the stock is already discounting a meaningful amount of bad news and may bounce on any sign of stabilization.
• Avoid adding to JPM purely on this note; the downgrade is more about company-specific cost and share issues than a read-through to the whole consumer staples group, so the cleaner expression is relative value, not sector-wide bearishness.
• Watch for any mention of fiscal 2027 margin bridge or integration cadence from GOJO: if management quantifies synergy timing, that is the earliest catalyst for a rerating and the point to cover downside hedges.